🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

    Pfizer Australia Pty Ltd

    Migraine (with or without aura)

    phase 3 small molecule active

    1 trial

  2. Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  3. Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  4. Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg

    Pfizer Australia Pty Ltd

    Alopecia areata

    phase 3 small molecule active

    1 trial

  5. Rocatinlimab, Placebo for AMG 451

    Amgen

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  6. Roflumilast (Daliresp®) 500µg, Roflumilast (Daliresp®) 250µg, CHF6001 DPI, Placebo to match CHF6001 DPI, CHF6001 DPI, Placebo to match Roflumilast (Daliresp®)

    Chiesi Farmaceutici S.p.A

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  7. Rosuvastatin Placebo, MK-0616 (Enlicitide chloride) Placebo, MK-0616, ROSUVASTATIN

    Merck Sharp and Dohme

    Hyperlipidemia

    phase 3 small molecule active

    1 trial

  8. Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.

    Protagonist Therapeutics, Inc

    Polycythemia Vera

    phase 3 small molecule active

    1 trial

  9. Ruxolitinib (INCB018424) cream, Ruxolitinib (INCB018424) cream, Vehicle (placebo) cream

    Incyte

    Vitiligo

    phase 3 small molecule active

    1 trial

  10. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  11. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  12. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  13. SALBUTAMOL , Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  14. SAMYR 400 mg compresse gastroresistenti, Samyr placebo (same excipient as SAMYR)

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  15. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics Inc

    endometrial cancer

    phase 3 small molecule active

    1 trial

  16. SELUMETINIB, SELUMETINIB, Placebo to match Selumetinib capsules, 10 and 25 mg.

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).

    phase 3 small molecule active

    1 trial

  17. SODIUM CHLORIDE, HYDROCORTISONE UPJOHN 100 mg, préparation injectable, Placebo of hydrocortisone 100 mg, Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult cardiac arrest patients with sustained ROSC and hemodynamic failure due to post-resuscitation syndrome

    phase 3 small molecule active

    1 trial

  18. SOTYKTU 6 mg film-coated tablets, Matching Placebo for Deucravacitinib, SOTYKTU 6 mg film-coated tablets, SOTYKTU 6 mg film-coated tablets, ZASOCITINIB, SOTYKTU 6 mg film-coated tablets, Matching Placebo for TAK-279

    Takeda

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  19. STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  20. Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial

  21. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  22. Saphnelo 300 mg concentrate for solution for infusion, Anifrolumab Placebo

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  23. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Autoimmune haemolytic anaemia

    phase 3 small molecule active

    1 trial

  24. Sar444671 placebo - matched placebo for test, Rilzabrutinib

    Sanofi-aventis Healthcare Pty Ltd

    Blood and lymphatic diseases

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources